about
Inhibition of West Nile Virus Multiplication in Cell Culture by Anti-Parkinsonian DrugsMolecular Mechanism of Adult Neurogenesis and its Association with Human Brain DiseasesPotential neuroprotective properties of epigallocatechin-3-gallate (EGCG)Unfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion DiseasesΑlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's DiseaseRedox control of protein degradationDirect and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein ToxicityDysregulation of glutathione homeostasis in neurodegenerative diseasesExploring the accessible conformations of N-terminal acetylated α-synucleinMitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's DiseasesThe contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseCurrent and Emerging Uses of Statins in Clinical Therapeutics: A ReviewImmunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's DiseaseGDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson diseaseA model of proteostatic energy cost and its use in analysis of proteome trends and sequence evolutionDisease-toxicant interactions in Parkinson's disease neuropathologyIntrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degenerationCopy number variability in Parkinson's disease: assembling the puzzle through a systems biology approachα-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotectionVPS35, the Retromer Complex and Parkinson's Disease.Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathiesMetabolic Investigations of the Molecular Mechanisms Associated with Parkinson's DiseaseReducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases.Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicityMultifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregatesCerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directionsThe pallidopyramidal syndromes: nosology, aetiology and pathogenesis.Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.The role of Galectin-3 in α-synuclein-induced microglial activation.Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregationA powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.An overview on the correlation of neurological disorders with cardiovascular disease.Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities.The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein.Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.Differential expression of alpha-synuclein in hippocampal neurons.Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease.
P2860
Q24273361-F436BEB8-0566-4FEE-89F3-CA881509C842Q26745434-7AE09E86-1884-4AD3-9908-802A218F3788Q26748605-5799533D-492E-4E3B-948C-CC7B8ED2664AQ26773443-14B23BA5-7374-4337-A3E9-2FAE0B50F48BQ26778937-AD9C4B25-0702-49EF-B74F-204A0D210A36Q26783566-F63AA66F-CC2C-415F-ADC2-659A8475ED2CQ26799306-AE8403A5-5B4B-4B8F-B9BD-185F88716B07Q26822726-13A79A51-A3E0-4BFC-A90A-A2716CE3B47BQ26852660-B3DDADAE-DABC-469D-BC8E-CD2D9D5CC1F2Q26859141-A9638809-3A8E-464E-A548-8B7A70ED23C7Q28068464-985ACE84-7813-42E9-A795-58B9BEA7F2D5Q28076346-BF656714-7A6A-4AB8-8165-F2E2D8870FA8Q28079187-2E33653A-5722-447D-A523-F295B8754C98Q28083626-6B405410-636D-46A0-9581-4BABFA5D8AB1Q28540274-32EAADCE-DD47-489D-90C1-FC940327523AQ29248297-68047CD2-4CD9-46A4-9A53-6C212E2A63F4Q30373366-DAC331B4-5E66-4715-84C9-8C9621BF0C56Q33364337-70822C08-F11D-4379-A2E0-F38A4B036C44Q33615657-6D09E931-2043-4503-8232-639F7FCE3D9BQ33708940-A564FA8F-2096-439C-9934-4BE2352033F5Q33715640-97DEB0C6-8666-4645-9376-305502C56A36Q33844949-D75BD403-57D6-4C8A-ADC1-8E1382574547Q33865366-F6776B51-88E2-4364-AE8E-B9BAE6AE683BQ33891870-66901B4F-D650-492A-826A-5987901168BEQ33947949-D0840F66-A561-4480-82EA-C4DAFC3C238EQ34003885-A35419C9-A15E-4B44-9F25-8E49E685AC28Q34074933-6A12CC68-FA35-4D87-9E3A-703CAB9696D1Q34237637-FE581AA6-D3BC-4EEC-BF71-F569EC78BF49Q34336776-EDD77991-B2C0-4BC1-A8A6-6206A410F960Q34441815-14C833FB-E6B7-4C1B-8A23-6A1EE814C02FQ34537231-BC319705-BD3C-4423-8FE2-F53AB6D93673Q34538864-B3EE0AF9-BB49-4EEC-827C-526E93B1D784Q34581042-0D79C6C8-4829-4F73-89C1-72A193979E9BQ34800195-94BE3954-0ABA-491D-984D-113C3DA56D5CQ34969902-BED93448-5161-47DD-9803-FC9F56DDF28FQ35002998-59E62CAA-5482-49CE-9651-EC5B88183030Q35058359-00339796-8FA9-440C-9F1F-FC09616DCD86Q35107062-41CD36B1-24BA-40BB-9251-7098F500FFC8Q35696249-706D20AC-5B4D-4A90-BBE2-10ED915AF570Q35716090-99111624-6284-40A8-ADB7-010C4F9DA99F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
α-Synuclein in Parkinson's disease.
@en
α-Synuclein in Parkinson's disease.
@nl
type
label
α-Synuclein in Parkinson's disease.
@en
α-Synuclein in Parkinson's disease.
@nl
prefLabel
α-Synuclein in Parkinson's disease.
@en
α-Synuclein in Parkinson's disease.
@nl
P2860
P1476
α-Synuclein in Parkinson's disease.
@en
P2093
Leonidas Stefanis
P2860
P304
P356
10.1101/CSHPERSPECT.A009399
P577
2012-02-01T00:00:00Z